Free Trial
NYSE:RMD

ResMed (RMD) Stock Price, News & Analysis

$244.87
+0.09 (+0.04%)
(As of 09/6/2024 ET)
Today's Range
$240.95
â–Ľ
$247.38
50-Day Range
$186.93
â–Ľ
$245.02
52-Week Range
$132.24
â–Ľ
$247.73
Volume
579,029 shs
Average Volume
1.04 million shs
Market Capitalization
$35.97 billion
P/E Ratio
37.61
Dividend Yield
0.87%
Price Target
$204.70

ResMed MarketRank™ Stock Analysis

Analyst Rating
Hold
2.45 Rating Score
Upside/​Downside
16.4% Downside
$204.70 Price Target
Short Interest
Bearish
6.66% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.60mentions of ResMed in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$20.81 M Sold Last Quarter
Proj. Earnings Growth
8.42%
From $8.91 to $9.66 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.26 out of 5 stars

Medical Sector

125th out of 910 stocks

Surgical & Medical Instruments Industry

18th out of 95 stocks

RMD stock logo

About ResMed Stock (NYSE:RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

RMD Stock Price History

RMD Stock News Headlines

ResMed Inc. (NYSE:RMD) Director Sells $479,800.00 in Stock
â­• [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
ResMed Inc. (NYSE:RMD) CEO Sells $3,145,832.75 in Stock
ResMed Insiders Sold US$16m Of Shares Suggesting Hesitancy
â­• [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
Needham Downgrades ResMed (RMD)
ResMed (NYSE:RMD) Stock Quotes, Forecast and News Summary
ResMed (NYSE:RMD) Downgraded to "Hold" at Needham & Company LLC
ResMed (NYSE:RMD) Downgraded to Hold at StockNews.com
NEXGEL (NASDAQ:NXGL) vs. ResMed (NYSE:RMD) Head-To-Head Survey
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 6/13 Dividend
5/08/2024
Dividend Payable
6/13/2024
Last Earnings
8/01/2024
Ex-Dividend for 9/19 Dividend
8/15/2024
Today
9/07/2024
Dividend Payable
9/19/2024
Next Earnings (Estimated)
10/24/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
76115210
Employees
9,980
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$204.70
High Stock Price Target
$251.00
Low Stock Price Target
$165.00
Potential Upside/Downside
-16.4%
Consensus Rating
Hold
Rating Score (0-4)
2.45
Research Coverage
11 Analysts

Profitability

Net Income
$1.02 billion
Pretax Margin
27.00%

Debt

Sales & Book Value

Annual Sales
$4.69 billion
Cash Flow
$9.22 per share
Book Value
$33.11 per share

Miscellaneous

Free Float
145,129,000
Market Cap
$35.97 billion
Optionable
Optionable
Beta
0.69

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Should I Buy ResMed Stock? RMD Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • ResMed Inc. reported strong earnings results, beating analysts' consensus estimates, indicating a healthy financial performance.
  • The company has a solid revenue growth rate, with a 6.9% increase compared to the same quarter last year, showcasing positive business momentum.
  • ResMed Inc. has a high return on equity of 25.00%, reflecting efficient utilization of shareholder funds to generate profits.
  • Recent insider transactions show confidence in the company, with insiders owning a notable percentage of the company's stock.
  • ResMed Inc.'s stock price has been trading up, indicating positive market sentiment and potential for capital appreciation.

Cons

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • The company's price-to-earnings ratio of 37.35 is relatively high, suggesting the stock may be overvalued compared to industry peers.
  • ResMed Inc. has a debt-to-equity ratio of 0.14, which may indicate a higher level of financial leverage and associated risks.
  • While the company has shown revenue growth, the price-to-earnings-growth ratio of 2.31 may imply a premium valuation relative to its growth prospects.
  • Institutional investors own a significant portion of the company's stock (54.98%), potentially leading to less influence for individual retail investors.
  • CEO and general counsel selling significant amounts of company stock may raise concerns about insider sentiment and future performance expectations.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 3, 2024. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

RMD Stock Analysis - Frequently Asked Questions

How have RMD shares performed this year?

ResMed's stock was trading at $172.02 on January 1st, 2024. Since then, RMD shares have increased by 42.3% and is now trading at $244.87.
View the best growth stocks for 2024 here
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Thursday, August, 1st. The medical equipment provider reported $2.08 earnings per share for the quarter, beating analysts' consensus estimates of $2.03 by $0.05. The company's revenue was up 6.9% compared to the same quarter last year.
Read the conference call transcript
.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does ResMed have any subsidiaries?

ResMed subsidiaries include these companies: Propeller Health, and Matrixcare.

Who are ResMed's major shareholders?

ResMed's top institutional shareholders include Bank of New York Mellon Corp (3.93%), Los Angeles Capital Management LLC (0.50%), Greenvale Capital LLP (0.49%) and Dimensional Fund Advisors LP (0.45%). Insiders that own company stock include Michael J Farrell, Robert Andrew Douglas, David Pendarvis, Brett Sandercock, Peter C Farrell, Justin Leong, Kaushik Ghoshal, Michael J Rider, Karen Drexler, Witte Jan De, Lucile Blaise, Carol Burt and James Hollingshead.
View institutional ownership trends
.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE) and Visa (V).

This page (NYSE:RMD) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners